Samvel Gyurdzhyan

ORCID: 0000-0002-3696-5192
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Advanced Radiotherapy Techniques
  • Cutaneous Melanoma Detection and Management
  • Radiation Dose and Imaging
  • Nonmelanoma Skin Cancer Studies
  • Management of metastatic bone disease
  • Infection Control and Ventilation
  • Advanced X-ray and CT Imaging
  • COVID-19 and healthcare impacts
  • AI in cancer detection
  • Oral health in cancer treatment
  • Cancer Diagnosis and Treatment
  • Head and Neck Cancer Studies
  • Cancer Genomics and Diagnostics
  • Prostate Cancer Diagnosis and Treatment

Stanford University
2021-2023

Stanford Medicine
2023

Palo Alto University
2021

University of California, Los Angeles
2014-2015

Dear Editor, There are limited data comparing the efficacy of ultrasound (US) to cross-sectional imaging (computed tomography [CT], positron emission [PET]-CT, or magnetic resonance [MRI]) for detection regional nodal recurrence in sentinel lymph node (SLN) biopsy-positive (SLNB-positive) cutaneous melanoma (CM) patients who forego completion dissection (CLND).1, 2 The seminal MSLT-2 and DeCOG-SLT trials SLNB-positive underwent US surveillance over CLND focused primarily on relapse free-...

10.1002/ski2.305 article EN cc-by Skin Health and Disease 2023-10-15

Purpose: To demonstrate feasibility and utility of a planning tool for post treatment reconstruction delivered dose distribution based on measured patient motion. The spinal cord limits in clinical use are planned dosimetric data which can significantly differ from dose. This be utilized to correlate outcomes Methods Materials: ur previous studies have shown that without intrafraction motion management, patients move up 3mm. current institutional protocol requires management by stereoscopic...

10.1118/1.4888295 article EN Medical Physics 2014-05-29

e21568 Background: Nodal ultrasound (US) is the preferred method for regional surveillance of clinically node-negative (cN0) primary cutaneous melanoma (CM) when sentinel lymph node biopsy (SLNB) not performed or unsuccessful, and pathologically node-positive (pN+) disease without completion dissection (CLND). Methods: Retrospective review was nodal US from 2011-2021 in SLNB-eligible cN0 CM patients SLNB deferred technically feasible ( i.e., failure lymphoscintigraphic dye migration) those...

10.1200/jco.2021.39.15_suppl.e21568 article EN Journal of Clinical Oncology 2021-05-20
Coming Soon ...